This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

PrEP for Your Patients' Needs: The PCP's Role in Preventing HIV

PrEP for Your Patients' Needs: The PCP's Role in Preventing HIV



Time to Complete

1 hour


December 28, 2017


December 28, 2018
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

This activity is jointly provided by Global Education Group and Integritas Communications.

Commercial Supporter

This activity is supported by an educational grant from Gilead Sciences, Inc.

Program Description

Although HIV incidence in the United States has declined over the last decade, the most recent data from the Centers for Disease Control and Prevention (CDC) identified 37,600 new HIV infections in 2014.1 Moreover, despite the overall gains, certain cohorts remain at particularly high risk of acquiring HIV, including men who have sex with men, heterosexual persons who engage in certain high-risk behaviors, and people who inject drugs.2 As part of a high-impact plan to reduce new HIV infections, the CDC has issued recommendations on the use of pre-exposure prophylaxis (PrEP)—a once-daily, FDA-approved antiretroviral therapy for HIV prophylaxis—as part of a comprehensive approach to reducing the risk of HIV acquisition by individuals in certain identified high-risk populations.3 Many health care providers, however, are unfamiliar with PrEP principles and protocols. This unfamiliarity is often further compounded by clinicians’ misinformation or personal attitudes that negatively affect the management of at-risk individuals.4 Primary care providers (PCPs) are very well-positioned to help close gaps in HIV prevention through guideline-driven testing, risk-reduction counseling, and effective patient education encompassing PrEP initiation and ongoing monitoring.5 In this Interactive ExchangeTM webcast, expert faculty will discuss recent trends in HIV incidence, CDC guidelines for HIV testing and identification of individuals at substantial risk, and protocols for determination of PrEP eligibility and longitudinal on-PrEP monitoring. The goal is to offer PCPs the tools they need to effectively provide HIV-prevention services.

1. CDC Fact Sheet. HIV Incidence: Estimated Annual Infections in the U.S., 2008-2014. 2017. Accessed December 14, 2017.
2. CDC. Surveillance Overview. Last updated January 2017. Accessed December 14, 2017.
3. US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States−2014: A Clinical Practice Guideline. Accessed December 14, 2017.
4. Smith DK, et al. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009–2015. PLoS One. 2016;11(6):e0156592.
5. Conniff J, Evensen A. Preexposure prophylaxis (PrEP) for HIV prevention: the primary care perspective. J Am Board Fam Med. 2016;29(1):143-151.

Intended Audience

The educational design of this activity addresses the needs of PCPs, including family medicine and internal medicine physicians, nurse practitioners, and physician assistants who contribute to or will contribute to human immunodeficiency virus (HIV) prevention and/or management services.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Demonstrate actionable knowledge of PrEP needs, principles, and goals, and fully implement the 2014 US Public Health Service (USPHS)/Centers for Disease Control and Prevention (CDC) clinical practice guideline: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014
  • Create open patient-provider dialogue and engage the patient as an active, educated participant in clinical decision-making and ongoing patient-centric monitoring
  • Provide proactive universal HIV-risk screening, establish substantial risk for HIV acquisition, determine PrEP eligibility, and assess patients’ PrEP readiness, preferences, and barriers to sustained adherence
  • Counsel patients regarding PrEP efficacy and safety; provide ongoing guideline-based clinical and laboratory monitoring, risk-reduction strategies, and treatment-adherence counseling to patients receiving PrEP

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University School of Medicine
Codirector, HIV/HCV Program Providence Hospital
Washington, DC

Dr. Elion discloses the following:
Speakers Bureaus: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc.
Advisory Boards: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., ViiV Healthcare
Expert Witness: Gilead Sciences, Inc.

Raphael J. Landovitz, MD, MSc
Associate Professor of Medicine
Associate Director, UCLA Center for Clinical AIDS Research and Education
Co-Director, UCLA Center for HIV Identification, Prevention and Treatment Services
David Geffen School of Medicine at UCLA
Los Angeles, CA

Dr. Landovitz discloses the following:
Contracted Research: Gilead Sciences, Inc.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME/CE activity:

Andrea Funk has nothing to disclose.
Ashley Marostica, RN, MSN, has nothing to disclose.
Jeanette Ruby, MD, has nothing to disclose.
Jim Kappler, PhD, has nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the posttest. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

If you have any other questions relating to your certificate or other issues with the activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue